▲ +137.74% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Adagene in the last 3 months. The average price target is $32.00, with a high forecast of $34.00 and a low forecast of $29.00. The average price target represents a 137.74% upside from the last price of $13.46.
The current consensus among 3 polled investment analysts is to buy stock in Adagene.
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.